Trillium Therapeutics Provides Update On Phase 1 Study Of TTI-621 And Dose Escalation To 2.0 MG/KG Level

NEXT STORY
Lexicon Pharmaceuticals Enters Into Agreement With TerSera Therapeutics for the Sale of XERMELO
PREV STORY
Airway Management Devices Global Market Report 2020-30: Covid 19 Implications and Growth
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

electroCore Announces Publication in Brain Stimulation Highlighting Non-Invasive Vagal Nerve Stimulation’s (nVNS) Potential Role in Treatment of Post-Traumatic Stress Disorder (PTSD)

author_avatar
NASDAQ Market News

EyePoint Pharmaceuticals Announces Fiscal 2018 Fourth Quarter & Full Year Financial Results Release Date and Conference Call Information

WATERTOWN, Mass., Sept. 05, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty ...

author_avatar
NASDAQ Market News

Checkpoint Therapeutics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

NEW YORK, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), ...

author_avatar
NASDAQ Market News